Adults with the most common group of neuroendocrine tumors now have a second FDA-approved version of lutetium Lu 177 dotatate, a targeted radiation drug that was previously sold in the U.S. only as Lutathera. Curium announced on Sept. 14 that the FDA approved Bexlutry for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, or GEP-NETs, including foregut, midgut, and hindgut tumors.
The company says Bexlutry is now available for prescribing. For patients, the practical significance is supply. Radioligand doses cannot be stockpiled, and a second manufacturer adds another source for a treatment that must be made and delivered on a tight schedule.
